Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.8
5.6
Journals
IJMS
Special Issues
Molecular Research and Treatment of Breast Cancer 3.0
ijms-logo
Submit to Special Issue Submit Abstract to Special Issue Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Molecular Research and Treatment of Breast Cancer 3.0

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: 20 September 2024 | Viewed by 1687

Special Issue Editor

Dr. Anna Kawiak

E-Mail Website
Guest Editor
Department of Biotechnology, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, 80-307 Gdansk, Poland
Interests: apoptosis; chemoresistance; cell signaling; natural compounds; anticancer drugs
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Breast cancer is one of the most frequently diagnosed malignancies in the female population. Due to its heterogeneity, the molecular mechanisms governing breast cancer development and progression are complex and impact prognosis and treatment efficacy. Advances in the field of molecular research have offered insight into the cellular mechanisms and genetic changes that characterize breast cancer subtypes. This has enabled the identification of key driver genes and aberrations that initiate tumor development and the delineation of signaling pathway alterations underlying breast tumor growth. Furthermore, the characterization of novel cellular targets has significantly contributed to the development of improved therapeutic and diagnostic strategies.

This Special Issue of IJMS will welcome original research and review articles with the aim of providing an overview of advances on the molecular bases of breast cancer. Research within this Issue will focus on the molecular aspects of breast cancer development, progression and invasion. The development and discovery of therapeutic agents, as well as strategies that increase the efficacy of standard therapy, will also be covered. Additionally, research related to therapy resistance and approaches that target tumor escape mechanisms will be included in the scope of this Issue.

More published papers can be found in the closed special issue:

Dr. Anna Kawiak
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biomarkers
  • breast cancer
  • cancer stem cells
  • cell signaling
  • circulating tumor cells
  • drug discovery
  • molecular diagnostics
  • molecular profiling
  • targeted therapy
  • therapy resistance

Related Special Issues

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

26 pages, 11017 KiB  
Article
Altered Phenotypes of Breast Epithelial × Breast Cancer Hybrids after ZEB1 Knock-Out
by Alexander Merckens, Mareike Sieler, Silvia Keil and Thomas Dittmar
Int. J. Mol. Sci. 2023, 24(24), 17310; https://doi.org/10.3390/ijms242417310 - 9 Dec 2023
Viewed by 1042
Abstract
ZEB1 plays a pivotal role in epithelial-to-mesenchymal transition (EMT), (cancer) cell stemness and cancer therapy resistance. The M13HS tumor hybrids, which were derived from spontaneous fusion events between the M13SV1-EGFP-Neo breast epithelial cells and HS578T-Hyg breast cancer cells, express ZEB1 and exhibit prospective [...] Read more.
ZEB1 plays a pivotal role in epithelial-to-mesenchymal transition (EMT), (cancer) cell stemness and cancer therapy resistance. The M13HS tumor hybrids, which were derived from spontaneous fusion events between the M13SV1-EGFP-Neo breast epithelial cells and HS578T-Hyg breast cancer cells, express ZEB1 and exhibit prospective cancer stem cell properties. To explore a possible correlation between the ZEB1 and stemness/ EMT-related properties in M13HS tumor hybrids, ZEB1 was knocked-out by CRISPR/Cas9. Colony formation, mammosphere formation, cell migration, invasion assays, flow cytometry and Western blot analyses were performed for the characterization of ZEB1 knock-out cells. The ZEB1 knock-out in M13HS tumor cells was not correlated with the down-regulation of the EMT-related markers N-CADHERIN (CDH2) and VIMENTIN and up-regulation of miR-200c-3p. Nonetheless, both the colony formation and mammosphere formation capacities of the M13HS ZEB1 knock-out cells were markedly reduced. Interestingly, the M13HS-2 ZEB1-KO cells harbored a markedly higher fraction of ALDH1-positive cells. The Transwell/ Boyden chamber migration assay data indicated a reduced migratory activity of the M13HS ZEB1-knock-out tumor hybrids, whereas in scratch/ wound-healing assays only the M13SH-8 ZEB1-knock-out cells possessed a reduced locomotory activity. Similarly, only the M13HS-8 ZEB1-knock-out tumor hybrids showed a reduced invasion capacity. Although the ZEB1 knock-out resulted in only moderate phenotypic changes, our data support the role of ZEB1 in EMT and stemness. Full article
(This article belongs to the Special Issue Molecular Research and Treatment of Breast Cancer 3.0)
►▼ Show Figures

Figure 1

Review

Jump to: Research

17 pages, 1957 KiB  
Review
Biological Roles and Clinical Applications of Exosomes in Breast Cancer: A Brief Review
by Han Wang, Ruo Wang, Kunwei Shen, Renhong Huang and Zheng Wang
Int. J. Mol. Sci. 2024, 25(9), 4620; https://doi.org/10.3390/ijms25094620 - 24 Apr 2024
Viewed by 382
Abstract
Breast cancer (BC) is a global health risk for women and has a high prevalence rate. The drug resistance, recurrence, and metastasis of BC affect patient prognosis, thus posing a challenge to scientists. Exosomes are extracellular vesicles (EVs) that originate from various cells; [...] Read more.
Breast cancer (BC) is a global health risk for women and has a high prevalence rate. The drug resistance, recurrence, and metastasis of BC affect patient prognosis, thus posing a challenge to scientists. Exosomes are extracellular vesicles (EVs) that originate from various cells; they have a double-layered lipid membrane structure and contain rich biological information. They mediate intercellular communication and have pivotal roles in tumor development, progression, and metastasis and drug resistance. Exosomes are important cell communication mediators in the tumor microenvironment (TME). Exosomes are utilized as diagnostic and prognostic biomarkers for estimating the treatment efficacy of BC and have the potential to function as tools to enable the targeted delivery of antitumor drugs. This review introduces recent progress in research on how exosomes influence tumor development and the TME. We also present the research progress on the application of exosomes as prognostic and diagnostic biomarkers and drug delivery tools. Full article
(This article belongs to the Special Issue Molecular Research and Treatment of Breast Cancer 3.0)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop